Gender effects on treatment response to interferon-beta in multiple sclerosis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Gender effects on treatment response to interferon-beta in multiple sclerosis. / Magyari, M; Koch-Henriksen, N; Laursen, B; Sørensen, P S.
In: Acta Neurologica Scandinavica. Supplementum, Vol. 130, No. 6, 12.2014, p. 374-379.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Gender effects on treatment response to interferon-beta in multiple sclerosis
AU - Magyari, M
AU - Koch-Henriksen, N
AU - Laursen, B
AU - Sørensen, P S
N1 - © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2014/12
Y1 - 2014/12
N2 - BACKGROUND: Gender appears to play a role in incidence and disease course of multiple sclerosis (MS).OBJECTIVE: The objective was to determine whether male and female patients with MS respond differently to interferon-beta treatment in terms of reduction in relapse rates.METHODS: We included all 2033 patients with relapsing-remitting MS who started treatment with interferon-beta from 1996 to 2003, identified from the Danish Multiple Sclerosis Treatment Register. We defined neutralizing antibody (NAb)-positive and NAb-negative periods in the single patient by the results of the NAb tests. Patients served as their own controls, and relapse rates were compared between NAb-negative and NAb-positive periods.RESULTS: NAbs significantly abrogated the interferon-beta treatment efficacy in both genders. The all-over women:men relapse rate ratio irrespective of NAb status was 1.47 (95%CI; 1.28-1.68). In a generalized linear Poisson models analysis with relapse counts as response variable, the main effects NAbs, sex, age at treatment start and number of relapses in 2 years before treatment start were strongly significant, but the effect of NAbs on relapse rates did not differ significantly between men and women.CONCLUSION: As NAbs influenced the on-treatment relapse rates strongly in both sexes but without statistical significant difference, there is no indication of different effects of interferon-beta in men or women.
AB - BACKGROUND: Gender appears to play a role in incidence and disease course of multiple sclerosis (MS).OBJECTIVE: The objective was to determine whether male and female patients with MS respond differently to interferon-beta treatment in terms of reduction in relapse rates.METHODS: We included all 2033 patients with relapsing-remitting MS who started treatment with interferon-beta from 1996 to 2003, identified from the Danish Multiple Sclerosis Treatment Register. We defined neutralizing antibody (NAb)-positive and NAb-negative periods in the single patient by the results of the NAb tests. Patients served as their own controls, and relapse rates were compared between NAb-negative and NAb-positive periods.RESULTS: NAbs significantly abrogated the interferon-beta treatment efficacy in both genders. The all-over women:men relapse rate ratio irrespective of NAb status was 1.47 (95%CI; 1.28-1.68). In a generalized linear Poisson models analysis with relapse counts as response variable, the main effects NAbs, sex, age at treatment start and number of relapses in 2 years before treatment start were strongly significant, but the effect of NAbs on relapse rates did not differ significantly between men and women.CONCLUSION: As NAbs influenced the on-treatment relapse rates strongly in both sexes but without statistical significant difference, there is no indication of different effects of interferon-beta in men or women.
U2 - 10.1111/ane.12277
DO - 10.1111/ane.12277
M3 - Journal article
C2 - 25208455
VL - 130
SP - 374
EP - 379
JO - Acta Neurologica Scandinavica, Supplement
JF - Acta Neurologica Scandinavica, Supplement
SN - 0065-1427
IS - 6
ER -
ID: 137742650